Mucuna pruriens seeds in treatment of Parkinson's disease: Pharmacological review

Oriental Pharmacy and Experimental Medicine

Volumn 13, Issue 3, 2013, Pages 165-174

  Kasture, Sanjay ^a,b   Mohan, Mahalaxmi ^c   Kasture, Veena ^a,b  

^a SANJIVANI COLLEGE OF PHARMACEUTICAL EDUCATION AND RESEARCH   (India)

^b Pinnacle Biomedical Research Institute   (India)

^c Priyadarshini College of Pharmaceutical Sciences   (India)

Author keywords

Antioxidants; Genistein; Mucuna pruriens; Neuroprotective; Unsaturated acids

Indexed keywords

5 METHOXY N,N DIMETHYLTRYPTAMINE; ALANINE; ANTIPARKINSON AGENT; ARGININE; BETA CARBOLINE; BUFOTENINE; CYSTINE; GALLIC ACID; GENISTEIN; GLUTATHIONE; HARMINE; HISTIDINE; LEVODOPA; LINOLENIC ACID; MUCUNA PRURIENS EXTRACT; N,N DIMETHYLTRYPTAMINE; NICOTINE; OLEIC ACID; PALMITIC ACID; PHOSPHATIDYLCHOLINE; PHYTIC ACID; PLANT EXTRACT; PROLINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SEROTONIN; STEARIC ACID; THREONINE; TRYPTOPHAN; TYROSINE; UBIDECARENONE; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; AYURVEDA; DISEASE COURSE; DYSKINESIA; HUMAN; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SUBSTANTIA NIGRA; VELVET BEAN;

EID: 84883361334     PISSN: 15982386     EISSN: 22111069     Source Type: Journal    
DOI: 10.1007/s13596-013-0126-2     Document Type: Review

References (136)

1. Ahmed M, Saleem S, Ahmad AS, Ansari MA, Yousuf S, Hoda MN, Islam F (2005) Neuroprotective effects of Withania somnifera on 6-hydroxydopamine induced Parkinsonism in rats. Hum Exp Toxicol 24: 137-147.
2. Ahmed M, Yousuf S, Khan MB, Hoda MN, Ahmad AS, Ansari MA, Ishrat T, Agrawal AK, Islam F (2006) Attenuation by Nardostachys jatamansi of 6-hydroxydopamine-induced parkinsonism in rats: behavioral, neurochemical, and immunohistochemical studies. Pharmacol Biochem Behav 83: 150-160.
3. Akaike A, Takada-Takatori Y, Kume T, Izumi Y (2010) Mechanisms of neuroprotective effects of nicotine and acetylcholinesterase inhibitors: role of alpha4 and alpha7 receptors in neuroprotection. J Mol Neurosci 40: 211-216.
4. Azcoitia I, Moreno A, Carrero P, Palacios S, Garcia-Segura LM (2006) Neuroprotective effects of soy phytoestrogens in the rat brain. Gynecol Endocrinol 22: 63-69.
5. Bains JS, Shaw CA (1997) Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death. Brain Res Rev 25: 335-358.
6. Baluchnejadmojarad T, Roghani M, Jalali MR, Bagheri NM (2009) Neuroprotective effect of genistein in 6-hydroxydopamine hemi-parkinsonian rat model. Phytother Res 23: 132-135.
7. Ban JY, Nguyen HT, Lee HJ, Cho SO, Ju HS, Kim JY, Bae K, Song KS, Seong YH (2008) Neuroprotective properties of gallic acid from Sanguisorbae radix on amyloid beta protein (25-35)-induced toxicity in cultured rat cortical neurons. Biol Pharm Bull 31: 149-153.
8. Barbeau A (1980) Lecithin in Parkinson's disease. J Neural Transm Suppl 16: 187-193.
9. Ben-Shachar D, Eshel G, Finberg JPM, Youdim MBH (1991) The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J Neurochem 56: 1441-1444.
10. Bhattacharya SK, Kumar A, Ghosal S (1995) Effects of glycowithanolides from Withania somnifera on an animal model of Alzheimer's disease and perturbed central cholinergic markers of cognition in rats. Phytother Res 9: 110-113.
11. Borah A, Kochupurackal P, Mohanakumar P (2007) Long-term l-dopa treatment causes indiscriminate increase in dopamine levels at the cost of serotonin synthesis in discrete brain regions of rats. Cell Mol Neurobiol 27: 985-996.
12. Bordia T, Campos C, Huang L, Quik M (2008) Continuous and intermittent nicotine treatment reduces L-3, 4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson's disease. J Pharmacol Exp Ther 327: 239-247.
13. Bordia T, Campos C, McIntosh JM, Quik M (2010) Nicotinic receptor-mediated reduction in L-DOPA induced dyskinesias may occur via desensitization. J Pharmacol Exp Ther 333: 929-938.
14. Bousquet M, Saint-Pierre M, Julien C, Salem N, Cicchetti F, Calon F (2008) Beneficial effects of dietary omega-3 polyunsaturated fatty acid on toxin-induced neuronal degeneration in an animal model of Parkinson's disease. FASEB J 22: 1213-1225.
15. Bressani R (2002) Factors influencing nutritive value in food grain legumes: Mucuna compared to other grain legumes. In: Food and feed from Mucuna: current uses and the way forward, workshop, CIDICCO, CIEPCA and World Hunger Research Center, Tegucigalpa, Honduras, 164-188.
16. A receptors. Biochem Pharmacol 68: 1631-1638.
17. Cenci MA (2007) Dopamine dysregulation of movement control in LDOPA-induced dyskinesia. Trends Neurosci 30: 236-243.
18. Charlton C (1997) Depletion of nigrostriatal and forebrain tyrosine hydroxylase by S-adenosyl methionine: a model that may explain the occurrence of depression in Parkinson's disease. Life Sci 61: 495-502.
19. Charlton C, Crowell B (1992) Parkinson's disease-like effects of S-adenosyl-L-methionine: effects of l-dopa. Pharmacol Biochem Behav 43: 423-431.
20. Chen L, Ding Y, Cagniard B, van Laar AD, Mortimer A, Chi W, Hastings TG, Kang UJ, Zhuang X (2008) Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice. J Neurosci 28: 425-433.
21. Damodaran M, Ramaswamy R (1937) Isolation of L-dopa from the seeds of Mucuna pruriens. Biochem J 31: 2149-2151.
22. Dexter DT, Carter CJ, Wells FR (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 52: 381-389.
23. Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FR, Daniel SE, Lees AJ, Jenner P, Marsden CD (1991) Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114: 1953-1975.
24. Dhanasekaran M, Tharakan B, Manyam BV (2008) Antiparkinson drug-Mucuna pruriens shows antioxidant and metal chelating activity. Phytother Res 22: 6-11.
25. Double KL, Maywald M, Schmittel M, Riederer P, Gerlach M (1998) In-vitro studies of ferritin iron release and neurotoxicity. J Neurochem 70: 2492-2499.
26. Duke JA (1981) Handbook of legumes of world economic importance. Plenum Press, New York, pp 170-173.
27. A receptor function by tyrosine kinase inhibitors and their inactive analogues. Mol Cell Neurosci 12: 300-310.
28. Foley P, Riederer P (2000) Influence of neurotoxins and oxidative stress on the onset and progression of Parkinson's disease. J Neurol 247: 82-94.
29. Frost D, Meechoovet B, Wang T, Gately S, Giorgetti M, Shcherbakova I, Dunckley T (2011) β-carboline compounds, including harmine, inhibit DYRK1A and tau phosphorylation at multiple Alzheimer's disease-related sites. PLoS One 6: e19264.
30. Fuller TA, Russchen FT, Price JL (1987) Sources of presumptive glutamatergic/aspartergic afferents to the rat ventral striatopallidal region. J Comp Neurol 258(3): I7-I338.
31. 2) and benzodiazepines receptors. Drug Alcohol Depend 60: 121-132.
32. Gockler N, Jofre G, Papadopoulos C, Soppa U, Tejedor FJ (2009) Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation. FEBS J 276: 6324-6337.
33. Godkar PB, Gordon RK, Ravindran A, Doctor BP (2004) Celastrus paniculatus seed water soluble extracts protect against glutamate toxicity in neuronal cultures from rat forebrain. J Ethnopharmacol 93: 213-219.
34. Graf E, Eaton JW (1990) Antioxidant activity of phytic acid. Free Radic Biol Med 8: 61-69.
35. Grella B, Dukat M, Young R, Teitler M, Davis KH, Gauthier CB, Glennon RA (1998) Investigation of hallucinogenic and related β-carbolines. Drug Alcohol Depend 50: 99-107.
36. Growdon JH, Melamed E, Logue M (1982) Effects of oral L-tyrosine administration on CSF tyrosine and homovanillic acid levels in patients with Parkinson's disease. Life Sci 30: 827-832.
37. Hall S, Rulledge JH, Schallert T (1992) MRI brain iron and 6-hydroxydopamine experimental Parkinson's disease. J Neurol Sci 113: 198-208.
38. Halliwell B (2001) Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging 18: 685-716.
39. Hauser RA, Lyons KE, McClain T (2009) Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease. Mov Disord 24: 979-983.
40. He Y, Thong PSP, Lee T, Leong SK, Shi CY, Wong PTH, Yuan SY, Watt F (1996) Increased iron in the substantia nigra of 6-OHDA induced parkinsonian rats: a nuclear microscopy study. Brain Res 735: 149-153.
41. Herraiz T, Chaparro C (2005) Human monoamine oxidase is inhibited by tobacco smoke: β-carboline alkaloids act as potent and reversible inhibitors. Biochem Biophys Res Commun 326: 378-386.
42. Hinz M (2009) Depression. In: Kohlstadt I (ed) Food and nutrients in disease management. CRC Press, Baton Rouge, pp 465-481.
43. Hinz M, Stein A, Uncini T (2011) Amino acid management of Parkinson's disease: a case study. Int J Gen Med 4: 165-174.
44. Horning MS, Blakemore LJ, Trombley PQ (2000) Endogenous mechanisms of neuroprotection: role of zinc, copper, and carnosine. Brain Res 852: 56-61.
45. Houghton PJ, Howes MJ (2005) Natural products and derivatives affecting neurotransmission relevant to Alzheimer's and Parkinson's disease. Neurosignal 14: 6-22.
46. A receptors. Mol Brain Res 67: 177-183.
47. Huang LZ, Campos C, Ly J, Carroll FI, Quik M (2011) Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats. Neuropharmacology 60: 861-868.
48. Husbands SM, Glennon RA, Gorgerat S, Gough R, Tyacke R, Nutt DJ, Lewis JW, Hudson AL (2001) β-carboline binding to imidazole receptors. Drug Alcohol Depend 64: 203-208.
49. Jellinger K, Paulus W, Grundke-Iqbal I (1990) Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J Neural Transm Park Dis Dement Sect 2: 327-340.
50. Jenner P (1998) Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov Disord 13: S24-S34.
51. Jenner P, Olanow CW (1996) Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 47: S161-S170.
52. Johnson S (2001) The multifaceted and widespread pathology of magnesium deficiency. Med Hypotheses 56: 163-170.
53. Kala BK, Mohan VR (2010) Chemical composition and nutritional evaluation of lesser known pulses of the genus, Mucuna. Adv Biores 1: 105-116.
54. Kalidass C, Mohan VR (2011) Nutritional and antinutritional composition of itching bean (Mucuna pruriens (L.) DC var. pruriens): an underutilized tribal pulse in Western Ghats. Tamil Nadu Trop Subtrop Agroecosyst 14: 279-293.
55. Kari AJ, Conn PJ, Niswender CM (2009) Glutamate receptors as therapeutic targets for Parkinson's disease. CNS Neurol Disord Drug Targets 8: 475-491.
56. Karobath M, Diaz J, Huttunen M (1971) The effect of l-dopa on the concentrations of tryptophan, tyrosine, and serotonin in the rat brain. Eur J Pharmacol 14: 393-396.
57. Kasture S, Pontis S, Pinna A, Schintu N, Spina L, Longoni R, Simola N, Ballero M, Morelli M (2009a) Assessment of symptomatic and neuroprotective efficacy of Mucuna pruriens extract in rodent model of Parkinson's disease. Neurotox Res 15: 111-122.
58. Kasture VS, Katti SA, Mahajan D, Wagh R, Mohan M, Kasture SB (2009b) Antioxidant and antiparkinson activity of gallic acid derivatives. Pharmacol Online 1: 385-395.
59. Katzenschlager R, Evans A, Manson A, Patsalos PN, Ratnaraj N, Watt H, Timmerman L, van der Giessen R, Lees AJ (2004) Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study. J Neurosurg Psychiatry 75: 1672-1677.
60. Kidd PM (1997) Glutathione: systemic protectant against oxidative and free radical damage. Altern Med Rev 2: 155-176.
61. Kidd PM (1999) Parkinson's disease as multifactorial oxidative neurodegeneration: implications for integrative management. Altern Med Rev 5: 502-545.
62. Kim H, Sablin SO, Ramsay RR (1997) Inhibition of monoamine oxidase A by β-carboline derivates. Arch Biochem Biophys 337: 137-142.
63. Kirtikar KR, Basu BD (1985) Indian medicinal plants. Mahendrapal Singh; Dehradun. India.
64. Ko KM, Godin DV (1990) Ferric ion-induced lipid peroxidation in erythrocyte membranes: effects of phytic acid and butylated hydroxytoluene. Mol Cell Biochem 95: 125-131.
65. 10 provides neuroprotection in iron-induced apoptosis in dopaminergic neurons. J Mol Neurosci 28: 125-141.
66. Kovacsova M, Barta A, Parohova J, Vrankova S, Pechanova O (2010) Neuroprotective mechanisms of natural polyphenolic compounds. Act Nerv Super Rediviva 52: 181-186.
67. Lauritzen I, Blondeau N, Heurteaux C, Widmann C, Romey G, Lazdunski M (2000) Polyunsaturated fatty acids are potent neuroprotectors. EMBO J 19: 1784-1793.
68. Lee CS, Han ES, Jang YY, Han JH, Ha HW, Kim DE (2000) Protective effect of harmalol and harmaline on MPTP neurotoxicity in the mouse and dopamine-induced damage of brain mitochondria and PC12 cell. J Neurochem 75: 521-531.
69. Lee SH, Park HJ, Cho SY, Jung HJ, Cho SM, Cho YS, Lillehoj HS (2005) Effects of dietary phytic acid on serum and hepatic lipid levels in diabetic KK mice. Nutr Res 25: 869-876.
70. Lieu CA, Kunselman AR, Manyam BV, Venkiteswaran K, Subramanian T (2010) A water extract of Mucuna pruriens provides long-term amelioration of parkinsonism with reduced risk for dyskinesias. Parkinsonism Relat Disord 16: 458-465.
71. Lieu CA, Venkiteswaran K, Gilmour TP, Rao AN, Petticoffer AC, Gilbert EV, Deogaonkar M, Manyam BV, Subramanian T (2012) The antiparkinsonian and antidyskinetic mechanisms of Mucuna pruriens in the MPTP-treated nonhuman primate. Evid Based Complement Alternat Med 1-10.
72. 2 in the production of HO: in vitro and in vivo. Free Radic Biol Med 16: 29-33.
73. Liu LX, Chen W-F, Xie J-X, Wong MS (2008) Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease. Neurosci Res 60: 156-161.
74. Lu Z, Nie G, Belton PS, Tang H, Zhao B (2006) Structure-activity relationship analysis of antioxidant ability and neuroprotective effect of gallic acid derivatives. Neurochem Int 48: 263-274.
75. Ma W, Yuan L, Yu H, Ding B, Xi Y, Feng J, Xiao R (2010) Genistein as a neuroprotective antioxidant attenuates redox imbalance induced by beta-amyloid peptides 25-35 in PC12 cells. Int J Dev Neurosci 28: 289-295.
76. Mahajani SS, Doshi VJ, Parikh KM, Manyam BV (1996) Bioavailability of L-DOPA from HP-200-a formulation of seed powder of Mucuna pruriens (Bak): a pharmacokinetic and pharmacodynamic study. Phytother Res 10: 254-256.
77. Maher P, Davis JB (1996) The role of monoamine metabolism in oxidative glutamate toxicity. J Neurosci 16: 6394-6401.
78. Mandel S, Weinreb O, Amit T, Youdim MBH (2005) Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. Brain Res Rev 48: 379-387.
79. Manyam BV (1990) Paralysis agitans and levodopa in Ayurveda: ancient Indian medical treatise. Mov Disord 5: 47-48.
80. Manyam BV, Dhanasekaran M, Hare TA (2004) Neuroprotective effects of the antiparkinson drug Mucuna pruriens. Phytother Res 9: 706-712.
81. Matsumoto K, Mizowaki M, Takayama H, Sakai S, Aimi N, Watanabe H (1997) Suppressive effect of mitragynine on the 5-methoxy-N, N-dimethyltryptamine-induced head-twitch response in mice. Pharmacol Biochem Behav 57: 319-323.
82. Mattiasson G, Shamloo M, Gido G, Mathi K, Tomasevic G, Yi S, Warden CH, Castilho RF, Melcher T, Gonzalez-Zulueta M, Nikolich K, Wieloch T (2003) Uncoupling protein-2 prevents neuronal death and diminishes brain dysfunction after stroke and brain trauma. Nat Med 9: 1062-1068.
83. 2 receptor ligands in conscious ocular hypertensive cynomolgus monkeys. J Pharmacol Exp Ther 306: 301-309.
84. McKenna DJ, Towers GH (1984) Biochemistry and pharmacology of tryptamines and beta-carbolines. A minireview. J Psychoactive Drugs 16: 347-358.
85. Mehta JC, Majumdar DN (1994) Indian medicinal plants V-Mucuna pruriens bark (Papilionaceae). Indian J Pharmacol 6: 92-94.
86. Miyamoto S, Kuwata G, Imai M, Nagao A, Terao J (2000) Protective effect of phytic acid hydrolysis products on iron-induced lipid peroxidation of liposomal membranes. Lipids 35: 1411-1414.
87. Moura DJ, Richter MF, Boeira JM, Henriques JAP, Saffi J (2007) Antioxidant properties of β-carboline alkaloids are related to their antimutagenic and antigenotoxic activities. Mutagenesis 22: 293-302.
88. Muñoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, Kirik D, Di Luca M, Björklund A, Bezard E, Carta M (2008) Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain 131: 3380-3394.
89. 1B receptor agonists in the rat Parkinson model. Exp Neurol 219: 298-307.
90. Nagashayana N, Sankarankutty P, Nampoothirir MR (2000) Association of L-dopa with recovery following ayurveda medication in Parkinson's disease. J Neurol Sci 176: 124-127.
91. Naidu PS, Singh A, Kulkarni SK (2003) Effect of Withania somnifera root extract on haloperidol-induced orofacial dyskinesia: possible mechanisms of action. J Med Food 6: 107-114.
92. Obata T (2003) Phytic acid suppresses 1-methyl-4-phenylpyridinium ion-induced hydroxyl radical generation in rat striatum. Brain Res 978: 241-244.
93. Pathan AA, Mohan M, Kasture AS, Kasture SB (2011) Mucuna pruriens attenuates haloperidol-induced orofacial dyskinesia in rats. Nat Prod Res 25: 764-771.
94. Pearce RK, Owen A, Daniel S (1997) Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. J Neural Transm 104: 661-677.
95. Perry TL, Godin DV, Hansen S (1982) Parkinson's disease: a disorder due to nigral glutathione deficiency? Neurosci Lett 33: 305-310.
96. Pimpinella G, Palmery M (1995) Interaction of β-carbolines with central dopaminergic transmission in mice: structure-activity relationships. Neurosci Lett 189: 121-124.
97. Polanski W, Reichmann H, Gille G (2011) Stimulation, protection and regeneration of dopaminergic neurons by 9-methyl-beta-carboline: a new anti-Parkinson drug? Expert Rev Neurother 11: 845-860.
98. Pytliak M, Vargová V, Mechírová V, Felšöci M (2011) Serotonin receptors-from molecular biology to clinical applications. Physiol Res 60: 15-25.
99. Quik M, Huang LZ, Parameswaran N, Bordia T, Campos C, Perez XA (2009) Multiple roles for nicotine in Parkinson's disease. Biochem Pharmacol 78: 677-685.
100. 2A receptors in MPTP monkeys and levodopa-induced dyskinesias. Eur J Neurosci 33: 1823-1831.
101. Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, Jellinger K, Youdim MBH (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52: 515-520.
102. Rommelspacher H, May T, Salewski B (1994) Harman (1-methyl-beta-carboline) is a natural inhibitor of monoamine oxidase type A in rats. Eur J Pharmacol 252: 51-59.
103. Ruscher K, Rzeczinski S, Thein E, Freyer D, Victorov IV, Lam TT, Dirnagl U (2007) Neuroprotective effects of the beta-carboline abecarnil studied in cultured cortical neurons and organotypic retinal cultures. Neuropharmacology 52: 1488-1495.
104. Sameri MJ, Sarkaki A, Farbood Y, Mansouri SM (2011) Motor disorders and impaired electrical power of pallidal EEG improved by gallic acid in animal model of Parkinson's disease. Pak J Biol Sci 15: 1109-1116.
105. Sathiayanarayanan L, Arulmozhi S (2007) Mucuna pruriens Linn: a comprehensive review. Pharmacognsy Rev 1: 157-162.
106. Schapira AHV, Mann VM, Cooper JM (1990) Anatomic and disease specificity of NADH, CoQ1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem 55: 2142-2145.
107. Schintu N, Frau L, Ibba M, Caboni P, Garau A, Carboni E, Carta AR (2009) PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease. Eur J Neurosci 29: 954-963.
108. Sechi G, Deledda MG, Bua G, Satta WM, Deiana GA, Pes GM (1996) Reduced intravenous glutathione in the treatment of early Parkinson's disease. Prog Neuro-Psychopharmacol Biol Psychiatry 20: 1159-1170.
109. Seidl SE, Potashkin JA (2011) The promise of neuroprotective agents in Parkinson's disease. Front Neurol 2: 68-87.
110. Sekar S, Elumalai P, Seppan P (2010) Effect of Mucuna pruriens on oxidative stress mediated damage in aged rat sperm. Int J Androl 33: 22-32.
111. Serrano-Dueñas M, Cardozo-Pelaez F, Sánchez-Ramos JR (2001) Effects of Banisteriopsis caapi extract on Parkinson's disease. Sci Rev Alt Med 5: 129-134.
112. Shanish AA, Roy PD, Vadivelan R, Jaysankar K, Vikram M, Nandini S, Sundeep M, Elango K, Suresh B (2010) Amelioration of CNS toxicities of L-dopa in experimental models of Parkinson's disease by concurrent treatment with Tinospora cordifolia hygeia. J Drug Med 2: 28-37.
113. Shen H-W, Jiang X-L, Winter JC, Yu A-M (2010) Psychedelic 5-methoxy-N, N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions. Curr Drug Metab 11: 659-666.
114. Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, Lew M (2002) Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 59: 1541-1550.
115. Smith RL, Canton H, Barrett RJ, Sanders-Bush E (1998) Agonist properties of N, N-dimethyltryptamine at serotonin 5-HT2A and 5-HT2C receptors. Pharmacol Biochem Behav 61: 323-330.
116. Song JX, Sze SC, Ng TB, Lee CK, Leung GP, Shaw PC, Tong Y, Zhang YB (2012) Anti-Parkinsonian drug discovery from herbal medicines: what have we got from neurotoxic models? J Ethnopharmacol 139: 698-711.
117. Squires EP, Hills CE, Rogers GJ, Garland P, Farley SR, Morgan NG (2004) The putative imidazoline receptor agonist, harmane, promotes intracellular calcium mobilization in pancreatic β-cells. Eur J Pharmacol 501: 31-39.
118. Sridhar KR, Bhat R (2007) Agrobotanical, nutritional and bioactive potential of unconventional legume-Mucuna. Livest Res Rural Dev 19: 126-130.
119. Temlett JA, Landsberg JP, Watt F, Grime GW (1994) Increased iron in the substantia nigra compacta of the MPTP lesioned hemiparkinsonian african green monkey: evidence from proton microprobe element microanalysis. J Neurochem 62: 134-146.
120. Tricklebank MD, Forler C, Middlemiss DN, Fozard JR (1985) Subtypes of the 5-HT receptor mediating the behavioural responses to 5-methoxy-N, N-dimethyltryptamine in the rat. Eur J Pharmacol 117: 15-24.
121. Tse SYH, Mak IT, Dickens BF (1991) Antioxidative properties of harmane and β-carboline alkaloids. Biochem Pharmacol 42: 459-464.
122. Uitti RJ, Rajput AH, Rozdilsky B (1989) Regional metal concentrations in Parkinson's disease, other chronic neurological diseases, and control brains. Can J Neurol Sci 16: 310-314.
123. Ulrich-Merzenich G, Panek D, Zeitler H, Wagner H, Vetter H (2009) New perspectives for synergy research with the "omic"-technologies. Phytomedicine 16: 495-508.
124. Ulrich-Merzenich G, Panek D, Zeitler H, Vetter H, Wagner H (2010) Drug development from natural products: exploring synergistic effects. Indian J Exp Biol 48: 208-211.
125. Umezawa H, Tobe H, Shibamoto N, Nakamura F, Nakamura K, Matsuzaki M, Takeuchi T (1975) Isolation of isoflavones inhibiting DOPA decarboxylase from fungi and streptomyces. J Antibiot 28: 947-952.
126. Vaidya AB, Rajgopalan TS, Mankodi NA (1978) Treatment of Parkinsons disease with the cowhage plant-Mucuna pruriens (Bak). Neurol India 36: 171-176.
127. Wagner H, Ulrich-Merzenich G (2009) Synergy research: approaching a new generation of phytopharmaceuticals. Phytomedicine 16: 97-110.
128. Wang Z-J, Li G-M, Tang W-L, Yin M (2006) Neuroprotective effects of stearic acid against toxicity of oxygen/glucose deprivation or glutamate on rat cortical or hippocampal slices. Acta Pharmacol Sin 27: 145-150.
129. Williams BB, Li D, Wegrzynowicz M, Vadodaria BK, Anderson JG, Kwakye GF, Aschner M, Erikson KM, Bowman AB (2010) Disease-toxicant screen reveals a neuroprotective interaction between Huntington's disease and manganese exposure. J Neurochem 112: 227-237.
130. Xu Q, Kanthasamy AG, Reddy MB (2011) Phytic acid protects against 6-hydroxydopamine-induced dopaminergic neuron apoptosis in normal and iron excess conditions in a cell culture model. Park Dis 2011: 1-6.
131. Yamaguchi T, Nagatsu T (1983) Effects of tyrosine administration on serum biopterin in normal controls and patients with Parkinson's disease. Science 219: 75-77.
132. Youdim MBH, Ben-Schachar D, Riederer P (1989) Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration? Acta Neurol Scand 126: 47-54.
133. Yritia M, Riba J, Ortuño J, Ramirez A, Castillo A, Alfaro Y, de la Torre R, Barbanoj MJ (2002) Determination of N, N-dimethyltryptamine and beta-carboline alkaloids in human plasma following oral administration of Ayahuasca. J Chromatogr B Anal Technol Biomed Life Sci 779: 271-281.
134. Zeevalk G, Manzino L, Sonsalla PK, Bernard LP (2007) Characterization of intracellular elevation of glutathione (GSH) with glutathione monoethyl ester and GSH in brain and neuronal cultures: relevance to Parkinson's disease. Exp Neurol 203: 512-520.
135. Zeevalk GD, Razmpour R, Bernard LP (2008) Glutathione and Parkinson's disease: is this the elephant in the room? Biomed Pharmacother 62: 236-249.
136. Zeng H, Chen Q, Zhao B (2004) Genistein ameliorates β-amyloid peptide (25-35)-induced hippocampal neuronal apoptosis. Free Radic Biol Med 36: 180-188.